Opendata, web and dolomites

EPIMAC SIGNED

The next generation epigenetic medicine for inflammation

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 EPIMAC project word cloud

Explore the words cloud of the EPIMAC project. It provides you a very rough idea of what is the project "EPIMAC" about.

epimac    overcome    kruidenier    cells    successful    good    treatment    hdac    inflammation    pharmaceutical    pipeline    multidisciplinary    reports    2010    pharmacology    clear    glaxosmithkline    disabling    precise    treating    academic    scientists    epigenetic    educate    clinical    time    therapeutic    deregulated    disease    master    named    suggest    ambition    compound    versatile    nicodeme    implementations    unclear    performance    doctoral    epinova    healthcare    bowel    worldwide    discovery    sme    epigenetics    world    diseases    etiology    tract    severe    mechanisms    area    al    therapeutics    et    cues    train    units    generation    companies    preclinical    gsk    aberrant    chronic    excitement    specializing    inhibitors    innovative    chroma    environmental    drug    gene    expression    modality    led    skilled    bear    conjunction    regulatory    ibd    validation    team    immuno    regulation    people    adjust    2012    strategies    millions    pursue    modifications    excellent    gastrointestinal    group    deacetylase    genetics    inflammatory    histone    nature   

Project "EPIMAC" data sheet

The following table provides information about the project.

Coordinator
AMC MEDICAL RESEARCH BV 

Organization address
address: MEIBERGDREEF 9
city: AMSTERDAM ZUIDOOST
postcode: 1105AZ
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Project website http://www.epimac.eu/
 Total cost 1˙294˙785 €
 EC max contribution 1˙294˙785 € (100%)
 Programme 1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers)
 Code Call H2020-MSCA-ITN-2014
 Funding Scheme MSCA-ITN-EID
 Starting year 2015
 Duration (year-month-day) from 2015-01-01   to  2019-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    AMC MEDICAL RESEARCH BV NL (AMSTERDAM ZUIDOOST) coordinator 1˙021˙497.00
2    GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD. UK (BRENTFORD) participant 273˙287.00
3    ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM NL (AMSTERDAM) participant 0.00
4    Eureka NL (Mechelen) partner 0.00
5    UNIVERSITAIR MEDISCH CENTRUM UTRECHT NL (UTRECHT) partner 0.00

Map

 Project objective

Epigenetic mechanisms allow cells to adjust gene expression in response to environmental cues. Increased understanding of this area has led to excitement about the potential of applying epigenetic regulation to drug discovery. EPIMAC aims to pursue the potential of epigenetics as a novel and innovative therapeutic modality for immuno-inflammatory diseases, in particular Inflammatory Bowel Disease (IBD). IBD is a severe and disabling chronic inflammation of the gastrointestinal tract affecting millions of people worldwide. Current treatment strategies are not successful because the precise etiology unclear. It is increasingly clear that deregulated epigenetic processes are associated with the aberrant inflammatory response seen in IBD. Recent reports suggest that inhibitors of epigenetic modifications developed by GlaxoSmithKline (GSK), such as histone deacetylase (HDAC) inhibitors, bear potential in treating inflammatory states (Nicodeme et al, Nature 2010; Kruidenier et al, Nature 2012). The EPIMAC consortium has the ambition to educate a group of next-generation scientists that master genetics, epigenetics, target discovery, pharmacology, preclinical validation and regulatory issues, and at the same time have a good understanding of clinical implementations of the drug pipeline of our pharmaceutical partner GSK. GSK is one of the world's leading research-based pharmaceutical and healthcare companies that aims to team up with academic partners in EPIMAC through its dedicated discovery performance unit named EpiNova in conjunction with 2 immuno-pharmacology units. An SME specializing in epigenetic compound targeting to inflammatory cells, Chroma Therapeutics, will contribute technology to EPIMAC. EPIMAC will educate and train these scientists by providing them with a versatile and multidisciplinary doctoral program, allowing them to become excellent scientists skilled to overcome the current challenges in IBD.

 Deliverables

List of deliverables.
Management, administration and finance 5d Documents, reports 2020-01-14 14:21:31
Research dissemination Other 2020-01-14 14:21:31
Management, administration and finance 5c Documents, reports 2019-07-10 15:36:56

Take a look to the deliverables list in detail:  detailed list of EPIMAC deliverables.

 Publications

year authors and title journal last update
List of publications.
2018 Andrew Y. F. Li Yim, Jessica R. de Bruyn, Nicolette W. Duijvis, Catriona Sharp, Enrico Ferrero, Wouter J. de Jonge, Manon E. Wildenberg, Marcel M. A. M. Mannens, Christianne J. Buskens, Geert R. D’Haens, Peter Henneman, Anje A. te Velde
A distinct epigenetic profile distinguishes stenotic from non-inflamed fibroblasts in the ileal mucosa of Crohn’s disease patients
published pages: e0209656, ISSN: 1932-6203, DOI: 10.1371/journal.pone.0209656
PLOS ONE 13/12 2019-07-10
2018 Annette E. Neele, Marion J.J. Gijbels, Saskia van der Velden, Marten A. Hoeksema, Marieke C.S. Boshuizen, Koen H.M. Prange, Hung-Jen Chen, Jan Van den Bossche, Cindy P.P.A. van Roomen, Annelie Shami, Johannes H.M. Levels, Jeffrey Kroon, Tina Lucas, Stefanie Dimmeler, Esther Lutgens, Menno P.J. de Winther
Myeloid Kdm6b deficiency results in advanced atherosclerosis
published pages: 156-165, ISSN: 0021-9150, DOI: 10.1016/j.atherosclerosis.2018.05.052
Atherosclerosis 275 2019-07-10
2016 Jan Van den Bossche, Jeroen Baardman, Natasja A. Otto, Saskia van der Velden, Annette E. Neele, Susan M. van den Berg, Rosario Luque-Martin, Hung-Jen Chen, Marieke C.S. Boshuizen, Mohamed Ahmed, Marten A. Hoeksema, Alex F. de Vos, Menno P.J. de Winther
Mitochondrial Dysfunction Prevents Repolarization of Inflammatory Macrophages
published pages: 684-696, ISSN: 2211-1247, DOI: 10.1016/j.celrep.2016.09.008
Cell Reports 17/3 2019-07-10
2016 Andrew Y. F. Li Yim, Nicolette W. Duijvis, Jing Zhao, Wouter J. de Jonge, Geert R. A. M. D’Haens, Marcel M. A. M. Mannens, Adri N. P. M. Mul, Anje A. te Velde, Peter Henneman
Peripheral blood methylation profiling of female Crohn’s disease patients
published pages: , ISSN: 1868-7075, DOI: 10.1186/s13148-016-0230-5
Clinical Epigenetics 8/1 2019-07-10
2017 Vincent A. van der Mark, Mohammed Ghiboub, Casper Marsman, Jing Zhao, Remco van Dijk, Johan K. Hiralall, Kam S. Ho-Mok, Zoë Castricum, Wouter J. de Jonge, Ronald P. J. Oude Elferink, Coen C. Paulusma
Phospholipid flippases attenuate LPS-induced TLR4 signaling by mediating endocytic retrieval of Toll-like receptor 4
published pages: 715-730, ISSN: 1420-682X, DOI: 10.1007/s00018-016-2360-5
Cellular and Molecular Life Sciences 74/4 2019-07-10

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EPIMAC" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EPIMAC" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.1.)

EAGRE (2020)

Eagre/Aegir: high-seas wave-impact modelling

Read More  

SuperCol (2020)

SuperCol: Rational design of super-selective and responsive colloidal particles for biomedical applications

Read More  

CORVOS (2019)

COmplement Regulation and Variations in Opportunistic infectionS

Read More